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OBJECTIVES: The present study aimed to evaluate the dynamics of CD28 and CD57 expression in CD8+ T lymphocytes during 
cytomegalovirus viremia in bone marrow transplant recipients.
METHODS: In a prospective study, blood samples were obtained once weekly once from 33 healthy volunteers and weekly from 
33 patients. To evaluate the expression of CD57 and CD28 on CD8+ T lymphocytes, flow cytometry analysis was performed on 
blood samples for four months after bone marrow transplant, together with cytomegalovirus antigenemia assays. 
RESULTS: Compared to cytomegalovirus-seronegative healthy subjects, seropositive healthy subjects demonstrated a higher 
percentage of CD57+ and a lower percentage of CD28+ cells (p<0.05). A linear regression model demonstrated a continuous 
decrease in CD28+ expression and a continuous increase in CD57+ expression after bone marrow transplant. The occurrence of 
cytomegalovirus antigenemia was associated with a steep drop in the percentage of CD28+ cells (5.94%, p<0.01) and an increase 
in CD57+ lymphocytes (5.60%, p<0.01). This cytomegalovirus-dependent effect was for the most part concentrated in the alloge-
neic bone marrow transplant patients. The development of acute graft versus host disease, which occurred at an earlier time than 
antigenemia (day 26 vs. day 56 post- bone marrow transplant), also had an impact on the CD57+ subset, triggering an increase of 
4.9% in CD57+ lymphocytes (p<0.05). 
CONCLUSION: We found continuous relative changes in the CD28+ and CD57+ subsets during the first 120 days post- bone 
marrow transplant, as part of immune system reconstitution and maturation. A clear correlation was observed between the expan-
sion of the CD57+CD28-CD8+ T lymphocyte subpopulation and the occurrence of graft versus host disease and cytomegalovirus 
viremia.
KEYWORDS: Cytomegalovirus; Graft versus host disease; Bone marrow transplant; CD57+ lymphocytes, immuno-constitu-
tion.
INTRODUCTION
Since the first bone marrow transplantations (BMTs) 
in the 1970s, many patients have benefited from their 
increasingly broad application.1 In recent years, more 
profound immunosuppression has been used to overcome 
problems associated with allogeneic BMTs and graft versus 
host disease (GVHD), and this has led to an increased 
frequency of life-threatening CMV infection in BMT 
recipients.2,3 Indeed, the incidence of CMV infection can 
reach 79% in CMV-seropositive recipients4 and 44% in 
CMV seronegative recipients with engraftment from CMV-
seropositive donors.2-8
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CD28, a co-stimulatory molecule present on the surface 
of T lymphocytes, is present in early stages of lymphocyte 
development and decreases after antigen stimulation.9,10 Its 
expression is, for the most part, mutually exclusive with that 
of CD57, which is expressed in 1 to 16.3% of circulating 
CD8+ T lymphocytes.11,12 Changes in CD28 and CD57 
expression in CD8+ T lymphocytes have been reported to 
occur in association with a number of different conditions, 
including human immunodeficiency virus infection,11,13,14 
rheumatoid arthritis,15 multiple myeloma,16,17 aging,18 BMT19 
and allogeneic transplants, specifically.11 However, the 
most commonly reported circumstance resulting in CD28 
downregulation and CD57 upregulation is CMV infection, 
either in isolation20,21 or in the setting of other conditions, 
such as HIV infection,22 aging,23 rheumatoid arthritis24 and 
stem cell transplantation.25 Different studies have suggested 
that increased CD57 expression and lack of CD28 expression 
in CD8+ T cells result from chronic antigen stimulation. 
These cells have been described as memory effector T-cells 
but lack a clear cytolytic function.26
The high incidence of CMV viremia and disease in BMT 
recipients makes these patients an ideal group in which to 
understand the relationship between CMV viremia and CD28 
and CD57 expression in CD8+ T lymphocytes. Therefore, a 
prospective evaluation of these patients during the first 120 
days after BMT was conducted, and the results suggested a 
correlation between CMV viremia and the expansion of the 
CD57+CD28-CD8+ T lymphocyte subset. 
MATERIALS AND METHODS
Volunteers and patients
This study was approved by the Ethics Committee of 
the University of São Paulo Medical School, and written 
informed consent was obtained from all participants, 
according to the guidelines of the Brazilian Ministry of 
Health. Thirty-three healthy volunteers, including some 
bone marrow donors, constituted the preliminary control 
lymphocyte population. Nine were seronegative for CMV 
antibodies, while 24 were seropositive. No statistically 
significant differences in age or gender were observed 
between the seronegative and seropositive groups. One blood 
draw was performed to obtain an EDTA-sample for flow 
cytometric analysis. 
Bone marrow transplant recipients at the BMT program 
of the Hematology and Hemotherapy Discipline at the 
University of São Paulo Medical School were prospectively 
enrolled in this trial. Thirty-three patients were eligible 
for the study. Twenty-two patients underwent allogeneic 
BMTs, and eleven patients received autologous BMTs. 
In the allogeneic BMT group, all patients received BMTs 
from a Human Leukocyte Antigen (HLA)-identical donor, 
and no patient received a T-cell depleted BMT. Of the 33 
BMT recipients, only five (15.5%) were seronegative for 
CMV. All of these were allogeneic BMT recipients. Of the 
22 allogeneic BMT recipients, only one (4.5%) involved a 
recipient and donor who were both CMV negative. Of the 
11 autologous BMT recipients, none was seronegative for 
CMV (Table 1).
Blood samples were taken from BMT recipients once a 
week, beginning at the start of the conditioning period and 
continuing until 120 days after the BMT. Samples were 
processed for lymphocyte immunophenotyping and CMV 
antigenemia. After BMT, all of the patients underwent 
weekly clinical examination. Imaging exams were performed 
at the discretion of the attending physician.
Table 1 - Patient demographics, BMT type, underlying dis-
ease, and immunosuppressive regimens used before BMT
Gender n (%)
Female 
Male
20 (60.6%) 
13 (39.4%)
Age Years (range) 
Mean 29 (20-34)
BMT type n (%)
Allogeneic 
Autologous
22 (66.6%) 
11 (33.3%)
Underlying disease n (%)
Chronic myelogenous leukemia 
Severe aplastic anemia 
Acute myelogenous leukemia 
Hodgkin´s lymphoma 
Other*
12 (36.4%) 
5 (15.2%) 
7 (21.2%) 
6 (18.2%) 
3 (9.1%)
Immunosuppressive conditioning regimen n (%)
Busulfan and melphalan 20 (60.6%)
Busulfan and cyclophosphamide 3 (9.1%)
Total body irradiation and melphalan 3 (9.1%)
Total body irradiation and cyclophosphamide 2 (6.1 %)
Other 5 (15.2%)
CMV serologic status pre-BMT
Positive 28 (84.8%)
Negative 5 (15.2%)
Donors’ CMV serologic status 
Positive 21 (95.5%)
Negative 1 (4.5%)
BMT: bone marrow transplant; *The three other cases were multiple my-
eloma, biphenotypic leukemia and breast cancer.
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Definitions
Active CMV infection was defined as the presence 
of at least one episode of positive antigenemia. Positive 
antigenemia was defined by the detection of one or more 
peroxidase-positive (dark-brown nuclear staining) cells in 
300,000 polymorphonuclear leukocytes. The presence of 
specific CMV antibodies was assessed by enzyme- immune-
asay (EIA), before transplantation and every two weeks 
thereafter, as previously described.4 CMV disease was defined 
according to Ljungman et al.29 Diagnosis and clinical grading 
of acute GVHD were performed according to Thomas et al.30 
For statistical analysis, GVHD was considered present when 
it was diagnosed as grade II or greater.
CMV surveillance and antiviral policies
The pp65 detection (antigenemia) assay was performed 
according to Van der Bij et al.,27 with minor modifications.28 
Whenever positive antigenemia was detected (≥ one positive 
cell/300,000 cells), the test was repeated every other day 
until the antigenemia resolved. When antigenemia of 
≥  two positive cells was detected, patients were started 
on preemptive intravenous ganciclovir (GCV) therapy at 
a dose of 5 mg/kg, twice daily for 14 days. If antigenemia 
remained positive after seven days, GCV was continued 
through the complete 21 days of therapy, or until the 
antigenemia resolved. In patients with antigenemia of 
fewer than two positive cells, GCV was not started, and 
the patient’s antigenemia levels were closely monitored. 
No secondary prophylaxis with ganciclovir was routinely 
used after preemptive therapy, except in patients with two 
or more episodes of positive antigenemia. When CMV 
disease was diagnosed, patients were treated with GCV at 
the same dose used for preemptive therapy. No intravenous 
immunoglobulin was used to treat CMV disease. 
All of the patients received HSV prophylaxis with 
acyclovir (400 mg, twice daily) until day 50 post-BMT. No 
prophylaxis for CMV disease was routinely used in this 
population.
Monoclonal antibodies and flow cytometry
CD57 fluorescein isothiocyanate (FITC, clone NK-
1), IgM FITC (isotype control, clone G155-228), CD28 
phycoerythrin (PE, clone CD28.2), IgG PE (isotype control, 
clone MOPC-21), CD8 Cy-Chrome (CyC, clone RPA-T8), 
and CD3 allophycocyanin (APC, clone UCHT1) monoclonal 
antibodies were obtained from PharMingen (San Diego, 
CA, USA). One hundred microliters of EDTA-treated blood 
were incubated at room temperature with a combination of 
monoclonal antibodies for 15 minutes in the dark and then 
treated with hemolysis buffer for ten minutes. Cells were 
washed and resuspended in phosphate-buffered saline (PBS) 
supplemented with 0.1% sodium azide for cytometric analysis. 
Cell samples were analyzed on a FACSCalibur flow cytometer 
(BDIS) equipped with argon and diode lasers for four-color, 
six-parameter detection. Acquisitions and analyses were 
performed using Cell Quest software (BDIS). Fluorescence 
voltages and compensation values were determined using 
single fluorochrome-stained cells from a healthy volunteer. 
After the acquisition of events in a live lymphocyte gate using 
forward and side scatter properties, CD3+/CD8+ lymphocytes 
were gated and represented in a CD28 and CD57 dot-plot 
(Figure 1A). Lymphocyte subpopulations were analyzed by 
Figure 1 - (A) Graphic representation of CD8+ T lymphocytes (using 
CD3+CD8+ dual staining over a lymphocyte gate) from CMV seronegative 
and CMV seropositive healthy subjects. Expression of CD28 and CD57 were 
essentially mutually exclusive. (B) Distribution of CD28 and CD57 in 9 CMV 
seronegative (CMV-) and 24 CMV seropositive (CMV+) healthy subjects. 
Statistically significant differences were observed in the distribution of both 
subsets correlating with CMV serostatus (arrows)  Median;  25%-75%; 
—|  Non-Outlier Min-Max;  Outliers;  Extremes
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the percentage of CD8+ T lymphocytes expressing different 
combinations of CD57 and CD28.
Statistical analysis
Results were plotted and analyzed using Microsoft 
Excel 2000 (Microsoft Corporation, Seattle, WA, USA), 
Statistic (StatSoft, Tulsa, OK, USA) and S-Plus (Mathsoft, 
Inc., Seattle, WA, USA). Group comparisons of pre-BMT, 
post-BMT, and final follow-up time points were performed 
using non-parametric Mann-Whitney tests, and p < 0.05 
was considered to be statistically significant. Changes in 
the percentages of each lymphocyte subpopulation among 
CD8+ T cells occurring during the 120-day follow-up period 
after BMT were summarized using linear regression models, 
and patients within each specific subgroup were compared 
using Student’s t-tests applied to the regression slopes. These 
summaries were then used to compare subgroups. Spearman 
tests were used to correlate time post-BMT with relative 
changes in CD28+CD57- and CD28-CD57+ subsets.
RESULTS
BMT patients dataset
From April 1998 to March 2000, 45 patients underwent 
BMT, and 33 were enrolled in this study. Five patients did not 
sign the informed consent form. Four patients died within the 
first 35 days after BMT and were excluded, and three patients 
were lost to follow-up. Therefore, 33 patients were included in 
the analysis. Patient characteristics are shown in Table 1.
Active CMV infection and disease
Twenty-three out of 33 BMT recipients (69.7%) had 
at least one episode of positive antigenemia (≥ 1 positive 
cell). Six of the 11 patients in the autologous BMT group 
(54.5%) and 17 of the 22 allogeneic BMT recipients (77.3%) 
developed positive antigenemia within 120 days post-BMT. 
The median time of antigenemia occurrence was 42.5 days in 
the autologous BMT recipients and 56 days in the allogeneic 
BMT recipients. The number of positive cells detected 
by antigenemia assays was higher in the allogeneic BMT 
recipients (median four positive cells, ranging from one to 
1064) than in the autologous BMT recipients (median one 
positive cell, ranging from one to two cells; p < 0.01, Mann-
Whitney test).
Of the 23 patients with positive antigenemia, two 
developed CMV disease during the 120-day follow-up period 
(8.7%). Both were allogeneic BMT recipients. One patient 
developed CMV pneumonia, and the other developed fever 
and pancytopenia. Interestingly, the first patient demonstrated 
a sharp drop in the percentage of CD57+CD28-CD8+ T 
lymphocytes at the onset of antigenemia. However, this 
lymphocyte population could not be analyzed in the second 
patient due to the low number of lymphocytes present during 
the pancytopenia.
Temporal occurrence of GVHD and CMV viremia
Acute GVHD, grade II or higher, was diagnosed in 12 
allogeneic BMT recipients (54.5%). In the 17 allogeneic 
BMT recipients with positive antigenemia, GVHD was 
diagnosed in ten patients (58.8%). In the five allogeneic 
BMT recipients with negative antigenemia, GVHD was 
present in two patients (40%). The median time to diagnosis 
of GVHD was 26 days and this preceded the occurrence of 
CMV antigenemia, which took place at a median of 56 days. 
The occurrences of GVHD as well as CMV viremia and 
disease are described in Table 2.
Table 2 - Patient clinical descriptions
Clinical description Group Number of patients (%) Total
Follow-up time 60-120 days 
≥120 days
7 (21.2%) 
26(78.8%) 
33
CMV antigenemia Positive* 
Negative**
23 (69.7%) 
10 (30.3%) 
33
CMV disease Yes 
No
2 (6.1%) 
31 (93.9%)
33
Acute GVHD Grade 0 or I 
Grade II to IV
10 (45.5%) 
12 (54.5%) 
22
Outcome Alive at day 120 
Death due to CMV disease 
Death due to other causes at day 120
32 (97.0%) 
none 
1 (3.0%) 
33
CMV: cytomegalovirus; GVHD: Graft-versus-host disease. *At least one positive CMV antigenemia assay during the first 120 days of follow-up. **No 
positive antigenemia detected during the first 120 days of follow-up.
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CMV serostatus and percentages of CD28+CD8+ and 
CD57+CD8+ T lymphocytes in healthy subjects
To evaluate the expression of CD28 and CD57 markers 
in CD8+ T lymphocytes, flow cytometric analyses were 
performed on EDTA-treated peripheral blood. The expression 
of CD28 was essentially mutually exclusive with CD57 in 
CD8+ T cells, such that a dual positive population was very 
rare (Figure 1A). To evaluate whether the expansion of the 
CD57+ cells was related to CMV, and to determine if the 
presence of CMV-specific antibodies was correlated with 
the distribution of CD8+ T lymphocyte subsets, 33 healthy 
volunteers were analyzed. As shown in Figure 1B, CMV-
seropositive subjects presented with a higher percentage 
of CD57+ cells and a lower percentage of CD28+ cells, 
compared to CMV-seronegative subjects.
After BMT, CD28+CD8+ T lymphocytes continuously 
decrease, while CD57+CD8+ T lymphocytes continu-
ously increase
Using a linear regression model, the dynamics of 
the CD28+ and CD57+ subpopulations within CD8+ 
T lymphocytes were analyzed. In general, after BMT, 
the percentage of CD28+ cells decreased, while that 
of CD57+ cells increased. These changes occurred at a 
relatively constant rate, independent of transplant type or 
the occurrence of CMV viremia or GVHD (Figure 2). On 
average, the baseline level of CD28+ cells (measured early 
during engraftment) was higher in the allogeneic BMT 
patients (72.11% at baseline, with -0.38%/day thereafter) 
than in the autologous BMT patients (46.23% at baseline, 
with -0.17%/day thereafter). Consistent with their mutually 
exclusive expression, the baseline level of CD57+ was lower 
in the allogeneic BMT group (14.40% at baseline, with 
+0.27%/day thereafter) than in the autologous BMT group 
(18.42% at baseline, with +0.12%/day thereafter). 
Influence of GVHD on CD57+CD8+ T lymphocytes
The presence of GVHD was also analyzed as a 
possible event influencing the changes seen in the CD8+ 
T lymphocyte subpopulations. Although both GVHD and 
CMV antigenemia were frequently diagnosed in the present 
series, they occurred at distinct times (day 26 vs. day 56), 
allowing us to examine independently the impact of each 
factor on changes in the T lymphocyte subpopulations. 
The occurrence of GVHD in 12 allogeneic patients had an 
impact on the CD57+ subset, triggering an increase of 4.9% 
in CD57+ lymphocytes (p < 0.05) (Table 3). However, daily 
changes in both the CD28+ and CD57+ populations were 
also observed in patients without GVHD, possibly reflecting 
immunologic reconstitution, as observed in patients without 
CMV viremia (Table 3). 
The subset of patients who developed GVHD was 
analyzed for the impact of positive CMV antigenemia on 
the distribution of CD57+CD28-CD8+ T lymphocytes. The 
majority of patients who developed GVHD had at least one 
positive CMV antigenemia assay during the follow-up period 
(10 out of 12, or 83.3%) (Table 4).
Temporal association between CMV antigenemia and 
changes in the CD28+CD8+ and CD57+CD8+ T lym-
phocyte subpopulations
To evaluate whether the occurrence of CMV viremia 
exerted an effect on the distribution of CD28+ and CD57+ 
Figure 2 - Relative decrease of CD57-CD28+ subset (A) and a relative 
increase of CD57+CD28- subset (B) in the CD8+ T lymphocyte population 
occur continuously after BMT, as assessed by Spearman’s correlation test
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Table 3 - Distribution of CD8+ T lymphocyte subpopulations at baseline and after allogeneic BMT, calculated daily changes 
during follow-up, and influence of GVHD
   
Group (number of patients) and lymphocyte subset Baseline 
(% of CD8+ T lymphocytes)
Calculated daily change 
(% of CD8+ T lymphocytes)
Change with GVHD 
(% of CD8+ T lymphocytes)
Allogeneic recipients without GVHD (n=10)
CD28+ 68.46 - 0.33* -
CD57+ 12.99 + 0.30* -
Allogeneic recipients with GVHD (n=12) **
CD28+ 68.00 - 0.34* - 3.23
CD57+ 19.22 + 0.22* + 4.90*
Allogeneic recipients who developed a positive CMV 
antigenemia (n=10)
CD28+ 65.80 - 0.33* - 2.04
CD57+ 20.10 + 0.23* + 4.13*
CMV: cytomegalovirus; GVHD: graft versus host disease. *p<0.05, Student’s t-test. **All developed positive antigenemia during study follow-up.
Table 4 - Distribution of CD8+ T lymphocyte subpopulations at baseline and after BMT, calculated daily changes during 
follow-up, and influence of CMV antigenemia, with patients stratified by type of BMT 
   
Group (number of patients) and lymphocyte subset Baseline 
(% of CD8+ T lymphocytes)
Calculated daily change 
(% of CD8+ T lymphocytes)
Change at onset of antigenemia 
(% of CD8+ T lymphocytes)
Without detectable CMV antigenemia (n=10)
CD28+ 63.29 - 0.18* -
CD57+ 8.66 + 0.12* -
With detectable CMV antigenemia (n=23)
CD28+ 60.40 - 0.30* - 5.95*
CD57+ 20.20 + 0.20* + 5.60*
          Autologous (n=6)
          CD28+ 44.90 - 0.16* - 2.18
          CD57+ 23.31 + 0.11 + 2.75
          Allogeneic (n=17)
          CD28+ 66.71 - 0.34* - 7.60*
          CD57+ 18.20 + 0.25* + 5.93*
Allogeneic recipients who developed GVHD (n=12)
CD28+ 65.80 - 0.33* - 7.30*
CD57+ 20.10 + 0.23* + 5.34*
Allogeneic recipients without GVHD but with 
detectable CMV antigenemia (n=7)
CD28+ 68.46 - 0.33* - 5.32*
CD57+ 12.99 + 0.30* + 5.47*
CMV: cytomegalovirus; GVHD: graft-versus-host disease. *p<0.05, Student’s t-test.
lymphocytes, the patients who experienced positive 
antigenemia during the follow-up period were compared 
to those who did not have any CMV-related episodes after 
BMT. The occurrence of positive antigenemia was associated 
with a steep drop in the percentage of CD28+ lymphocytes 
(5.95%, p < 0.01), along with an increase of CD57+ 
lymphocytes (5.60%, p < 0.01) (Table 4). Representative 
cases depicting the association of CMV antigenemia with 
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CD8+ T cell subset changes are shown in Figure 3.
The abrupt changes observed in these subpopulations did 
not influence the calculated daily rate of change for CD28 or 
CD57 expression observed before the CMV viremia. Thus, 
after the CMV event, the daily rates of change of both CD28 
and CD57 expression returned to the same pattern present 
prior to the viremia. This strongly suggested that the abrupt 
changes were related to the antigenemia rather than to a 
natural phenomenon associated with immune reconstitution 
after transplant.
The CMV-triggered changes in CD8+ T lymphocyte 
subsets occurred primarily in the allogeneic BMT patients, 
as shown in Table 3. In addition, in the seven patients 
without GVHD who experienced positive antigenemia, a 
significant increase in the CD57+ subpopulation could also 
be observed (Table 4). Two examples are shown in figures 3B 
and 3E. Figure 3B represents a patient with GVHD and no 
detectable CMV antigenemia who experienced an increase 
in the CD57+ subset, while Figure 3E represents a patient 
who developed both GVHD, which had minor effects on the 
CD57+ subset, and CMV antigenemia, which had a more 
pronounced effect on both the CD57+ and CD28+ subsets.
DISCUSSION
In this prospective study, we confirmed a correlation 
between CMV seropositivity and relative expansion of the 
CD57+CD28-CD8+ T lymphocyte population in healthy 
volunteers. We also took advantage of the high incidence 
of CMV viremia in BMT patients to study the temporal 
association between CMV viremia and the relative expansion 
of this cell subset. In addition to describing the close 
relationship between CMV reactivation and expansion of 
this CD8+ subset in BMT recipients,31,32 we were also able 
to detect an effect of GVHD on the CD57+CD28-CD8+ T 
lymphocyte subpopulation.
CD57, formerly known as leu7, is a glycoprotein 
found mostly on NK cells and CD8+ T lymphocytes. It is 
thought to identify a late memory effector subset of CD8+ 
T lymphocytes.14,33,34 The increase in this subset after 
solid organ transplantation35 or BMT36 has been described 
previously, and these cells have been shown to be of donor 
origin, as the myeloablative conditioning regimens used 
prior to transplant completely eliminate recipient T-cells.37 
We were able to confirm this result and also to demonstrate 
that this increase happens in a slow and continuous fashion, 
continuing up to four months after BMT, independently 
of CMV viremia or GVHD diagnosis. Together with the 
increase in the CD57+CD28- subset, a slow and continuous 
decrease in the CD57-CD28+ subset was also observed. This 
behavior possibly reflects an immunologic reconstitution 
process that occurs after severe induced immunodeficiency. 
During the first 120 days following BMT,that is characterized 
by pronounced immune system suppression, patients face 
repeated immunological stimuli through re-exposure to 
and/or reactivation of infectious agents and, with allogeneic 
BMTs, exposure to alloantigens. Once activated to begin the 
maturation process, CD8+ T lymphocytes in BMT recipients 
Figure 3 - CD28+ (open circles) and CD57+ (closed circles) subpopula-
tion percentages among CD8+ T lymphocytes in selected BMT recipients. 
Arrows represent positive antigenemia and arrowheads represent GVHD. 
(A) Allogeneic BMT in a patient who did not develop CMV antigenemia or 
GVHD. (B) Allogeneic BMT in a patient who developed GVHD. (C) and 
(D) Allogeneic BMT in two patients with CMV antigenemia. (E) Allogeneic 
BMT in a patient who developed both GVHD and CMV antigenemia at dis-
tinct moments during follow-up. (F) Autologous BMT in a patient developing 
CMV antigenemia on two occasions during follow-up
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tend to lose CD28 expression and, as we have demonstrated, 
acquire the expression of the CD57 surface molecule.
More recently, investigators have described an 
increased production of interferon gamma (IFNγ), either in 
response to mitogens38 or CMV-derived antigens,34 and an 
oligoclonal, CMV-specific expansion39,40 in the CD57+CD8+ 
T lymphocyte subset. Furthermore, Khan et al. have 
demonstrated that CMV-specific CD8+ cells with cytotoxic 
activity more frequently express surface CD57 than they do 
CD28.41 Thus, while some have suggested that these cells 
have undergone replicative senescence or clonal exhaustion 
and lack a protective function,42 other authors have proposed 
that this subset plays a regulatory role, modulating immune 
responses to large, harmful antigenic stimuli.43 Still others 
have suggested that these cells have a cytotoxic, protective 
role, characterized by production of IFN-γ, IL-2, and IL-4 
and by expression of high levels of perforin.41,42,44 
An association between expansion of the CD57+CD8+ 
T lymphocyte subset and CMV infection in BMT was 
first suggested by Dolstra et al., who described a higher 
number of these cells in those patients that developed CMV 
infection.45 In two patients, CMV-specific cytotoxicity 
activity was also demonstrated in vitro46. Our findings 
strongly suggest an association between CMV viremia and 
the relative expansion of this subset, with an impressive 
increase of greater than 6% at the time of CMV antigenemia 
occurrence. The observed temporal association between 
CMV viremia and the relative increase in the CD57+CD28-
CD8+ T lymphocyte subset suggests the presence of an 
antigen-specific response driven by CMV (Figure 4). 
However, when patients were divided into allogeneic 
and autologous BMT groups, we could demonstrate this 
association only in the allogeneic BMT group. 
Autologous BMT recipients had a lower percentage 
of CD28+ cells (46.23% vs. 72.11%) and a higher 
percentage of CD57+ cells (18.42% vs. 14.4%) shortly after 
transplantation, possibly reflecting a better ability to contain 
CMV viremia, which, again, was consistently less prevalent 
here than in the allogeneic BMT group. The early availability 
of this antigen-specific T cell subset may account for the 
lower incidence of CMV viremia and the lower levels of 
antigen detection in the case of CMV reactivation, that would 
result in smaller relative changes in both the CD28+ and 
CD57+ subsets. We were not able, however, to correlate an 
increased proportion of CD57+ cells with a lower incidence 
of CMV reactivation in the allogeneic BMT recipients. 
Analysis of these cases revealed that some patients with high 
levels of CD57+ T cells did reactivate. Those patients that 
did so were generally those who developed acute GVHD 
(higher than grade II) (Figure 3E). 
Thus, it appeared that the expansion of CD57+CD28-
CD8+ T lymphocytes was not exclusively related to CMV 
viremia. In fact, GVHD had a similar effect on the relative 
increase of this cell population. Acute GVHD is a frequent 
and early event in the course of allogeneic BMT, usually 
preceding antigenemia by several weeks. In our cohort, acute 
GVHD occurred at day 26 post-BMT, while antigenemia 
was diagnosed at day 56 post-BMT. This difference 
allowed us to independently analyze the effects of these two 
phenomena. GVHD involves donor-derived cytotoxic CD8+ 
T lymphocytes reacting against recipient tissues, and results 
in dramatic immune cell activation.47 The striking association 
between GVHD and increased CD57 expression in the present 
study suggests an additional pathway for CD8+ T lymphocyte 
differentiation, probably triggered by alloantigens. Other 
groups have previously described an increase in the CD28- 
subset of CD8+ lymphocytes related to GVHD, but none 
evaluated expression of the CD57 marker.48,49 A more recent 
study observed an increase in CD57+CD8+ T cells in pediatric 
BMT recipients with a diagnosis of GVHD but was not able 
to demonstrate a temporal correlation between the increase 
of this subset and GVHD diagnosis.42 In contrast, we did not 
find a marked effect of GVHD on the CD28+ subset, as was 
previously suggested by Lee et al.48
We were able to demonstrate continuous relative changes 
in the CD28+ and CD57+ subsets during the first 120 days 
after both allogeneic and autologous BMTs, as part of immune 
reconstitution and maturation post-BMT. More importantly, 
a clear correlation was observed between the expansion of 
the CD57+CD28-CD8+ T lymphocyte subpopulation and 
CMV viremia, suggesting an important role for this cell 
subset in the context of CMV disease. Supporting this idea, 
the expansion of this cell population was associated with the 
appearance of CMV viremia and was generally followed by a 
retraction coincident with resolution of the viremia. However, 
further studies are needed to address whether CD57+CD8+ T 
Figure 4 - Proposed model for CD8+ T lymphocyte subset reconstitution 
after BMT and the effect of CMV viremia. A continuous relative decrease in 
CD28+ cells, along with a continuous relative increase in CD57+, takes place 
after BMT engraftment. The occurrence of CMV viremia exerts a substantial 
effect on this system, causing a steep incline in both curves
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cells have a protective role in the control of CMV infection 
and disease, or whether they are a hallmark of the chronic 
antigenic stimulation induced by CMV.21,26 
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